Across rheumatic diseases

Risk of cancer induced by human papillomavirus in patients with immune-mediated inflammatory diseases: a nationwide matched cohort study

RMD OpenPublished Nationwide matched cohort study

Main finding · HPV-induced cancer or severe dysplasiaResult — go to the resultAge-adjusted HR 1.99 95% CI 1.80–2.20

Authors' conclusion

Patients with IMIDs are almost two times as likely to develop HPV-associated cancer or severe dysplasia, particularly at cervical, vulvar, vaginal and anal sites, compared with matched controls.

Study context

Population
Patients with immune-mediated inflammatory diseases (IMIDs) and matched controls, French nationwide hospital database, 2016–2023mean follow-up 4.11 (2.47) years
Participants
122,316 vs 316,047
Exposure
Patients with IMIDs vs matched controls
  • IMIDsn = 122,316
  • Controlsn = 316,047reference
Outcome
Occurrence of HPV-induced cancer or severe dysplasia
Methodological detailsFrench nationwide hospital medical information database, multivariable competing risk analysis
  • French nationwide hospital medical information database
  • Multivariable competing risk analysis

Main finding

HPV-induced cancer or severe dysplasia

Age-adjusted HR

1.99

95% CI 1.80–2.20

IMIDsvs Controls
age-adjusted HR 1.99 (95% CI 1.80–2.20)

As reported in the abstract

Observational data: associations, not effects.

Further findings

Individual human papillomavirus (HPV)-induced cancer types

Increased risk in IMIDs for all types of HPV-induced cancer except penile cancer

Risk factors for HPV-induced cancer/severe dysplasia within IMIDs (multivariable competing risk analysis)

Female, HR
5.88 (95% CI 4.01 to 8.61)
Systemic lupus erythematosus (SLE), HR
2.08 (95% CI 1.70 to 2.55)
Age under 65 years, HR
2.09 (95% CI 1.70 to 2.57)
CKD, HR
1.44 (95% CI 1.18 to 1.77)

Original publication

Risk of cancer induced by human papillomavirus in patients with immune-mediated inflammatory diseases: a nationwide matched cohort study. RMD Open. Published 15 July 2026. doi:10.1136/rmdopen-2026-006927

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.